Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real-world clinical setting. Analyzing data from 1,001 patients recruited to the UK-PSC research cohort, we evaluated clinical variables for their association with 2-year and 10-year outcome through Cox-proportional hazards and C-statistic analyses. We generated risk scores for short-term and long-term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty-six percent of the derivation cohort were transplanted or died over a cumulative follow-up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10-year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant-free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2-year and 10-year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK-PSC risk scores were well-validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)-DR*03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK-PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real-world scoring system to identify those patients most likely to die or require liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359 · cited 1×
“Time-to-event analysis was conducted using Cox’s proportional hazards model, ensuring at least 10 events per risk factor would be included in the model.(26) To facilitate accurate risk prediction, events were truncated at 10 years of follow-up.”
MethodBoonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 1×
“(13,14) However, many studies evaluating risk prediction models in PSC have been limited by sample size, tertiary center recruitment bias, failure to control for the interaction of variables with one another, and lack of validation.(16) With the exception of the revised Mayo Clinic model (Mayo), previous prognostic mo…”
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 2×
“Primary sclerosing cholangitis (PSC) is a chronic fibrosing cholestatic liver disease that is frequently associated with inflammatory bowel disease (IBD).(1) Disease progression culminates in end-stage liver disease and a high likelihood of death without liver transplantation.”
BackgroundWeismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533
Self-citationLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498 · cited 1×
“8 and above.(31,32) Although in PSC, the serum ALP was not associated with short-term outcome, the prognostic importance as a longer-term predictor of clinical events is highlighted by its inclusion in our long-term risk score.”
BackgroundSelf-citationCollins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Annals of Internal Medicine · doi:10.7326/l15-5093-2 · Cited by 493
Natural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2616 · Cited by 391
Self-citationThe UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3745 · Cited by 357
Self-citationCarbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Self-citationCorpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., Carrat, F., & Chazouillères, O. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.030 · Cited by 300
Reporting methods in studies developing prognostic models in cancer: a review
Mallett, S., Royston, P., Dutton, S., Waters, R., & Altman, D. G. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-20 · Cited by 206 · cited 1×
“We selected variables for the final risk score using backward elimination, with removal of risk factors not significant at the 10% level.(27) Continuous variables were assessed for nonlinear association using cubic splines.”
MethodEnhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Vesterhus, M., Hov, J. R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., Andersen, I. M., Næss, S., Thorburn, D., Saffioti, F., et al. (2015) · Hepatology · doi:10.1002/hep.27825 · Cited by 138 · cited 1×
“(17-21) Although it is not unexpected that histology is a predictor of outcome, as surrogates of liver fibrosis such as enhanced liver fibrosis score and transient elastography perform equally well(22,23), a simpler prognostic scoring is warranted.”
BackgroundSelf-citationTrivedi, P. J., Corpechot, C., Pares, A., & Hirschfield, G. M. (2016) · Hepatology · doi:10.1002/hep.28128 · Cited by 71 · cited 1×
“(6-8) Clinical course is variable, and efforts to individualize risk prediction are important for patients, clinicians, and trials of experimental agents.(9) Existing studies suggest that various clinical factors may predict the risk of adverse outcome.”
BackgroundSelf-citation
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationRecent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Self-citationTrivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.049 · Cited by 183
Self-citation
Metadata
- Authors
- Goode, E. C., Clark, A. B., Mells, G. F., Srivastava, B., Spiess, K., Gelson, W. T. H., Trivedi, P. J., Lynch, K. D., Castren, E., Vesterhus, M. N., Karlsen, T. H., Ji, S., Anderson, C. A., Thorburn, D., Hudson, M., Heneghan, M. A., Aldersley, M. A., Bathgate, A., Sandford, R. N., Alexander, G. J., Chapman, R. W., Walmsley, M., Hirschfield, G. M., & Rushbrook, S. M.
- Venue
- Hepatology
- Published
- 2019-05
- Volume
- 69
- Issue
- 5
- Pages
- 2120-2135
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2905044063
- Cited by
- 106
- References
- 14
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.